Compare · FEED vs STE
FEED vs STE
Side-by-side comparison of ENvue Medical Inc. (FEED) and STERIS plc (Ireland) (STE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FEED and STE operate in Industrial Specialties (Health Care), so they compete in similar markets.
- STE is the larger of the two at $21.87B, about 22988.8x FEED ($951,430).
- Over the past year, FEED is down 98.8% and STE is down 7.4% - STE leads by 91.3 points.
- STE has been more active in the news (4 items in the past 4 weeks vs 1 for FEED).
- STE has more recent analyst coverage (17 ratings vs 0 for FEED).
- Company
- ENvue Medical Inc.
- STERIS plc (Ireland)
- Price
- $0.87-75.77%
- $222.35-0.91%
- Market cap
- $951,430
- $21.87B
- 1M return
- +0.00%
- +6.90%
- 1Y return
- -98.79%
- -7.45%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 1
- 4
- Recent ratings
- 0
- 17
STERIS plc (Ireland)
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. This segment offers its products and services to acute care hospitals and other healthcare settings. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The company is based in Dublin, Ireland.
Latest FEED
- SEC Form 8-K filed by ENvue Medical Inc.
- ENvue Medical Provides Nasdaq Listing Update
- ENvue Medical Resumes U.S. Commercial Shipments of NanoVibronix PainShield® and Begins Fulfilling Open Distributor Orders
- SEC Form EFFECT filed by ENvue Medical Inc.
- ENvue Medical Selected to Exhibit ENvue™ Navigation Platform at Vizient Innovative Technology Exchange
- SEC Form 8-K filed by ENvue Medical Inc.
- ENvue Medical, Inc. Announces 1-for-12 Reverse Stock Split
- ENvue Medical Announces Exclusive UroShield® Distribution Agreement with Minimum Purchase Commitments of Approximately $2.6 Million
- SEC Form 10-Q filed by ENvue Medical Inc.
- SEC Form NT 10-Q filed by ENvue Medical Inc.
Latest STE
- SEC Form 8-K filed by STERIS plc (Ireland)
- Xodus Medical Announces Agreement to Be Acquired by STERIS (NYSE: STE)
- STERIS Expands Healthcare Consumables Offering with Definitive Agreement to Acquire Xodus Medical, a Specialty Surgical Products Business Focused on Patient and OR Staff Safety
- SEC Form 4 filed by STERIS plc (Ireland)
- STERIS to Present at the Morgan Stanley Healthcare Conference
- SEC Form 144 filed by STERIS plc (Ireland)
- SEC Form 4 filed by Director Shapiro Louis
- Director Sohi Mohsen exercised 4,058 units of Ordinary Shares at a strike of $86.23 and sold $956,795 worth of Ordinary Shares (4,058 units at $235.78) (SEC Form 4)
- SEC Form 4 filed by Director Shah Nirav R
- SEC Form 4 filed by Director Martin Paul Edward